Acevedo-Vásquez Eduardo, Ponce de León Darío, Gamboa-Cárdenas Rocío
School of Medicine, Universidad Nacional Mayor de San Marcos, Lima, Perú.
Rheum Dis Clin North Am. 2009 Feb;35(1):163-81. doi: 10.1016/j.rdc.2009.03.008.
New drug classes, biologics, have been developed over the past 10 years based on human or chimeric antibodies against cytokines or receptors with pivotal roles in the inflammatory pathways of immune-mediated inflammatory disease. Anti-tumor necrosis factor agents carry the largest infection risk of all the biologics, predisposing patients to mycobacterial infections. Patients receiving biologics are at higher risk for developing tuberculosis. New cases of tuberculosis or reactivation of latent tuberculosis infections may occur during the course of treatment, so a high level of vigilance is highly recommended.
在过去10年中，基于针对细胞因子或受体的人源或嵌合抗体开发了新的药物类别，即生物制剂，这些细胞因子或受体在免疫介导的炎症性疾病的炎症途径中起关键作用。抗肿瘤坏死因子药物在所有生物制剂中具有最大的感染风险，使患者易患分枝杆菌感染。接受生物制剂治疗的患者患结核病的风险更高。在治疗过程中可能会出现新的结核病病例或潜伏性结核感染的复发，因此强烈建议保持高度警惕。
